PepGen Inc.
Close on Oct 19, 2026
- Market cap
- $186.85M
- P/E (TTM)
- –
- Dividend yield
- –
About PepGen
Pharmaceutical Preparations, SIC 2834
PepGen Inc. is a clinical-stage biotechnology company that develops oligonucleotide therapeutics for severe neuromuscular and neurologic disorders. The company utilizes an Enhanced Delivery Oligonucleotide platform that conjugates cell-penetrating peptides with synthetic oligonucleotides to improve delivery into target cells and tissues, including skeletal and cardiac muscle. Its lead candidate, PGN-EDODM1, targets the underlying genetic defect of myotonic dystrophy type 1 by binding to toxic expanded RNA repeats to correct cellular splicing. Because the company has no approved commercial treatments, its therapeutic candidates are intended for patients living with myotonic dystrophy type 1.
The company is headquartered in Boston, Massachusetts. Its clinical activities span several countries, having conducted trials in the United States, Canada, and the United Kingdom, and received regulatory clearances to conduct studies in South Korea, Australia, and New Zealand.
Summary of the business section of PepGen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PepGen Inc.
- Headquarters
- Boston, MA
- Address
- 1 Marina Park Drive, Suite 900 02210
- Phone
- (703) 456-8000
- Website
- pepgen.com
- Employees
- 56, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, CA, USA
Stock & identifiers
- Ticker
- PEPG
- Exchange
- Nasdaq
- IPO date
- May 9, 2022
- Shares outstanding
- 69M, Aug 2, 2026
- Public float
- $16.90M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1835597
- CUSIP
- 713317105
- ISIN
- US7133171055
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James G. McArthur | President and CEO, Director | 296,457 |
| Kasra Kasraian | Chief Technical Officer | 50,074 |
| Noel Donnelly | Chief Financial Officer | 111,603 |
| Paul Streck | EVP, Head of R&D | 76,226 |
| Joseph Vittiglio | Chief Business & Legal Officer | 65,717 |
| Mary Beth DeLena | General Counsel | 14,968 |
| Laurie Keating | Director | 4,166 |
| Joshua Resnick | Director | – |
| Capital Healthcare Fund LP RA | Director | 18,554,273 |
| Howard Mayer | Director | – |
| Lisa Wyman | Director | – |
| Mitchell H. Finer | Director | – |
| Habib J. Dable | Director | – |
| Rajeev M. Shah | Director | – |
| Peter Kolchinsky | Director | 9,179,273 |
| Ra Capital Management, L.P. | Director | – |
| RA Capital Nexus Fund II, L.P. | Director | – |
| Heidi Henson | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 56 full-time employees, of whom 17 have Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 9, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| May 3, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |